Last reviewed · How we verify
AskBio009
At a glance
| Generic name | AskBio009 |
|---|---|
| Also known as | BAX 335 |
| Sponsor | Baxalta now part of Shire |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AskBio009 CI brief — competitive landscape report
- AskBio009 updates RSS · CI watch RSS
- Baxalta now part of Shire portfolio CI